Skip to main content

Advertisement

Log in

Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Purpose

To develop an integrated mechanism-based modeling approach for the interspecies scaling of pharmacokinetic (PK) and pharmacodynamic (PD) properties of type I interferons (IFNs) that exhibit target-mediated drug disposition (TMDD).

Methods

PK and PD profiles of human IFN-β1a, IFN-β1b, and IFN-α2a in humans, monkeys, rats, and mice from nine studies were extracted from the literature by digitization. Concentration-time profiles from different species were fitted simultaneously using various allometric relationships to scale model-specific parameters.

Results

PK/PD profiles of IFN-β1a in humans and monkeys were successfully characterized by utilizing the same rate constant parameters and scaling the volume of the central compartment to body weight using an allometric exponent of 1. Concentration and effect profiles of other IFNs were also well described by changing only the affinity of the drug to its receptor. PK profiles in rodents were simulated using an allometric exponent of −0.25 for the first-order elimination rate constant, and no receptor-binding was included given the lack of cross-reactivity.

Conclusions

An integrated TMDD PK/PD model was successfully combined with classic allometric scaling techniques and showed good predictive performance. Several parameters obtained from one IFN can be effectively shared to predict the kinetic behavior of other IFN subtypes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

REFERENCES

  1. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. Human interferons alpha, beta and omega. Growth Factors. 2004;22:243–51.

    Article  PubMed  CAS  Google Scholar 

  2. Samarajiwa SA, Wilson W, Hertzog PJ, Interferons TI. Genetics and structure. In: Meager A, editor. The interferons: characterization and application. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA; 2006. p. 3–34.

    Google Scholar 

  3. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res. 1999;19:1069–98.

    Article  PubMed  CAS  Google Scholar 

  4. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem. 2007;282:20053–7.

    Article  PubMed  CAS  Google Scholar 

  5. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem. 1987;56:727–77.

    Article  PubMed  CAS  Google Scholar 

  6. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci. 1992;29:307–41.

    Article  PubMed  CAS  Google Scholar 

  7. Chiang J, Gloff CA, Soike KF, Williams G. Pharmacokinetics and antiviral activity of recombinant human interferon-beta ser17 in African green monkeys. J Interferon Res. 1993;13:111–20.

    PubMed  CAS  Google Scholar 

  8. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther. 2003;306:262–70.

    Article  PubMed  CAS  Google Scholar 

  9. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56:248–52.

    Article  PubMed  CAS  Google Scholar 

  10. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507–32.

    Article  PubMed  CAS  Google Scholar 

  11. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006;72:1–10.

    Article  PubMed  CAS  Google Scholar 

  12. Mager DE, Jusko WJ. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-β 1a in humans. Pharm Res. 2002;19:1537–43.

    Article  PubMed  CAS  Google Scholar 

  13. Segrave AM, Mager DE, Charman SA, Edwards GA, Porter CJ. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther. 2004;309:1085–92.

    Article  PubMed  CAS  Google Scholar 

  14. Woo S, Krzyzanski W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn. 2007;34:849–68.

    Article  PubMed  CAS  Google Scholar 

  15. Adolph EF. Quantitative relations in the physiological constitutions of mammals. Science. 1949;109:579–85.

    Article  PubMed  Google Scholar 

  16. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol. 1983;245:R768–775.

    PubMed  CAS  Google Scholar 

  17. Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm. 1973;1:435–61.

    Article  PubMed  CAS  Google Scholar 

  18. Tang H, Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos. 2005;33:1297–303.

    Article  PubMed  CAS  Google Scholar 

  19. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res. 1991;8:1351–9.

    Article  PubMed  CAS  Google Scholar 

  20. Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci. 2004;93:177–85.

    Article  PubMed  CAS  Google Scholar 

  21. Tang H, Mayersohn M. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci. 2006;95:1783–99.

    Article  PubMed  CAS  Google Scholar 

  22. Woo S, Jusko WJ. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos. 2007;35:1672–8.

    Article  PubMed  CAS  Google Scholar 

  23. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res. 2000;20:857–66.

    Article  PubMed  CAS  Google Scholar 

  24. Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22:1589–96.

    Article  PubMed  CAS  Google Scholar 

  25. Kushnaryov VM, MacDonald HS, Sedmak JJ, Grossberg SE. Murine interferon-beta receptor-mediated endocytosis and nuclear membrane binding. Proc Natl Acad Sci U S A. 1985;82:3281–5.

    Article  PubMed  CAS  Google Scholar 

  26. Bino T, Edery H, Gertler A, Rosenberg H. Involvement of the kidney in catabolism of human leukocyte interferon. J Gen Virol. 1982;59:39–45.

    Article  PubMed  CAS  Google Scholar 

  27. Bino T, Madar Z, Gertler A, Rosenberg H. The kidney is the main site of interferon degradation. J Interferon Res. 1982;2:301–8.

    PubMed  CAS  Google Scholar 

  28. Rosenberg H, Madar Z, Gertler A, Rubinstein M, Bino T. The fate of [125I]-labeled human leukocyte-derived alpha interferon in the rat. J Interferon Res. 1985;5:121–7.

    PubMed  CAS  Google Scholar 

  29. Interferon: The 50th Anniversary, Springer-Verlag, Berlin, 2007.

  30. Sharma A, Ebling WF, Jusko WJ. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci. 1998;87:1577–84.

    Article  PubMed  CAS  Google Scholar 

  31. Mager DE, Jusko WJ. Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther. 2001;70:210–6.

    Article  PubMed  CAS  Google Scholar 

  32. Chiang J, Gloff CA, Yoshizawa CN, Williams GJ. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm Res. 1993;10:567–72.

    Article  PubMed  CAS  Google Scholar 

  33. Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008;83:909–12.

    Article  PubMed  CAS  Google Scholar 

  34. Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet. 2009;24:16–24.

    Article  PubMed  CAS  Google Scholar 

  35. Cosson VF, Fuseau E, Efthymiopoulos C, Bye A. Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. J Pharmacokinet Biopharm. 1997;25:149–67.

    Article  PubMed  CAS  Google Scholar 

  36. Jolling K, Perez Ruixo JJ, Hemeryck A, Vermeulen A, Greway T. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci. 2005;24:465–75.

    Article  PubMed  CAS  Google Scholar 

  37. Gloff C, Wills R. Pharmacokinetics and metabolism of therapeutic cytokines. New York: Plenum; 1992.

    Google Scholar 

  38. McKenna SD, Vergilis K, Arulanandam AR, Weiser WY, Nabioullin R, Tepper MA. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice. J Interferon Cytokine Res. 2004;24:119–29.

    Article  PubMed  CAS  Google Scholar 

  39. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther. 2001;297:1059–66.

    PubMed  CAS  Google Scholar 

  40. Wills RJ, Dennis S, Spiegel HE, Gibson DM, Nadler PI. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharmacol Ther. 1984;35:722–7.

    PubMed  CAS  Google Scholar 

  41. Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant alpha A interferon following I.V. infusion and bolus, I.M., and P.O. administrations to African green monkeys. J Interferon Res. 1984;4:399–409.

    PubMed  CAS  Google Scholar 

  42. Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, Morgenroth B, Richter W, Chou RC. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci. 1995;84:1285–90.

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS

This work was supported, in part, by Grant GM57980 from the National Institutes of Health (D.E.M.), the Center for Protein Therapeutics, University at Buffalo, SUNY (L.K. and J.M.H.), and the University at Buffalo—Pfizer Strategic Alliance (A.K.A.). Partial results of this study were presented in a poster at the 2009 AAPS Annual Meeting in Los Angeles, CA.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Donald E. Mager.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kagan, L., Abraham, A.K., Harrold, J.M. et al. Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons. Pharm Res 27, 920–932 (2010). https://doi.org/10.1007/s11095-010-0098-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-010-0098-6

KEY WORDS

Navigation